Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S, Alsaleem M, Monteiro CJ, Bhardwaj K, Joosten SEP, Fujii T, Shirabe K, Green AR, Ellis IO, Rakha EA, Mongan NP, Heery DM, Zwart W, Oesterreich S, Johnston SJ. Kurozumi S, et al. Among authors: alsaleem m. Breast Cancer Res. 2020 Aug 11;22(1):85. doi: 10.1186/s13058-020-01324-4. Breast Cancer Res. 2020. PMID: 32782013 Free PMC article.
Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA. Kurozumi S, et al. Among authors: alsaleem m. Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28. Breast Cancer Res Treat. 2018. PMID: 30056565
Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA. Kurozumi S, et al. Among authors: alsaleem m. Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2. Breast Cancer Res Treat. 2019. PMID: 30941650
A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.
Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA. Kurozumi S, et al. Among authors: alsaleem m. Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22. Br J Cancer. 2019. PMID: 31114020 Free PMC article.
Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.
Ogden A, Bhattarai S, Sahoo B, Mongan NP, Alsaleem M, Green AR, Aleskandarany M, Ellis IO, Pattni S, Li XB, Moreno CS, Krishnamurti U, Janssen EA, Jonsdottir K, Rakha E, Rida P, Aneja R. Ogden A, et al. Among authors: alsaleem m. Sci Rep. 2020 Feb 20;10(1):3009. doi: 10.1038/s41598-020-59514-1. Sci Rep. 2020. PMID: 32080212 Free PMC article.
PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression.
Gagliano T, Shah K, Gargani S, Lao L, Alsaleem M, Chen J, Ntafis V, Huang P, Ditsiou A, Vella V, Yadav K, Bienkowska K, Bresciani G, Kang K, Li L, Carter P, Benstead-Hume G, O'Hanlon T, Dean M, Pearl FM, Lee SC, Rakha EA, Green AR, Kontoyiannis DL, Song E, Stebbing J, Giamas G. Gagliano T, et al. Among authors: alsaleem m. J Clin Invest. 2020 Jun 1;130(6):3188-3204. doi: 10.1172/JCI128313. J Clin Invest. 2020. PMID: 32125284 Free PMC article.
102 results